Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05892068 | A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02624973 | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial(PETREMAC) | active not recruiting | Phase 2 | 200 | Haukeland University HospitalOTHER | 1 | Feb 12, 2026 |
| clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT04754191 | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer(ENCORE) | active not recruiting | Phase 2 | 34 | University of UtahOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial(REVELUTION) | active not recruiting | Phase 2 | 94 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05673772 | Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer(SOLAR) | active not recruiting | Phase 2 | 364 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 72 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05714891 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 4 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02143726 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | active not recruiting | Phase 2 | 35 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04977024 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | active not recruiting | Phase 2 | 63 | GeoVax, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05197426 | A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | active not recruiting | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 11, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)(iMMagine-1) | active not recruiting | Phase 2 | 136 | Kite, A Gilead CompanyINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03474094 | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy(RT-Immune) | active not recruiting | Phase 2 | 62 | Centre Leon BerardOTHER | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04078295 | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 125 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | active not recruiting | Phase 2 | 151 | Regeneron PharmaceuticalsINDUSTRY | 8 | Feb 10, 2026 | clinicaltrials |
| NCT06939283 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 100 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05286060 | Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer(GENUINE) | active not recruiting | Phase 2 | 56 | Yonsei UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02747004 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer(Next MONARCH 1) | active not recruiting | Phase 2 | 234 | Eli Lilly and CompanyINDUSTRY | 14 | Feb 6, 2026 | clinicaltrials |
| NCT03405792 | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)(2-THE-TOP) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03513562 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | active not recruiting | Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03749018 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 30 | David Bond, MDOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | active not recruiting | Phase 2 | 173 | Nuvation Bio Inc.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04884282 | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)(COMBI-TED) | active not recruiting | Phase 2 | 105 | Fondazione Ricerca TraslazionaleOTHER | 3 | Feb 6, 2026 | clinicaltrials |
| NCT06175390 | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer(SKYLINE) | active not recruiting | Phase 2 | 81 | Institut CurieOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01815359 | ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis(ICARuS) | active not recruiting | Phase 2 | 292 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05418972 | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma(Neo ReNi II) | active not recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06268015 | Botensilimab and Balstilimab Optimization in Colorectal Cancer(BBOpCo) | active not recruiting | Phase 2 | 16 | Nicholas DeVito, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07242365 | Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy | active not recruiting | Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03808662 | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | active not recruiting | Phase 2 | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04223596 | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients(CUBIK) | active not recruiting | Phase 2 | 33 | Fundación GECPOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04562480 | Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk | active not recruiting | Phase 2 | 120 | Mayo ClinicOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05563844 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | active not recruiting | Phase 2 | 74 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 500 | FBD Biologics LimitedINDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT00882895 | Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04067037 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | active not recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04454437 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments | active not recruiting | Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Feb 13, 2026source: clinicaltrials